- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Papers: 18 May 2019 - 24 May 2019
Pharmacology/Drug Development
PAIN TYPE:
Migraine/Headache
2019 May 16
J Headache Pain
20
1
The treatment of migraine is impeded by several difficulties, among which insufficient headache relief, side effects, and risk for developing medication overuse headache (MOH). Thus, new acutely acting antimigraine drugs are currently being developed, among which the small molecule CGRP receptor antagonists, gepants, and the 5-HT receptor agonist lasmiditan. Whether treatment with these drugs carries the same risk for developing MOH is currently unknown.